编者按:冷存储大隐静脉同种异体移植用于血液透析血管通路的结局
这项回顾性双中心研究纳入2016年1月至2020年12月间因无法建立自体动静脉瘘而接受冷存储大隐静脉同种异体移植(CSVA)进行血液透析血管通路的109例患者,分析其通畅率、并发症与再干预情况。结果显示一年和两年通畅率及感染率较低,考虑竞争风险后一年和两年通路丢失率分别为9.2%和18%。作者认为CSVA可作为ePTFE移植物的潜在替代选择。
要点
- 109例无自体动静脉瘘建立条件的患者接受CSVA,平均年龄67.2±13.6岁。
- 一年原发、原发辅助和继发通畅率分别为37.6%、59.0%和73.3%,两年分别为19.9%、42.5%和54.9%。
- 平均随访26±18个月,感染率4.6%,考虑竞争风险后一年和两年通路丢失率9.2%和18%。
核心结论
- CSVA通畅率与ePTFE移植物相当且感染率低,为静脉资源耗竭且存在血管通路感染危险因素的患者提供了潜在的替代选择。
研究设计与样本
- 回顾性双中心研究,纳入2016年1月至2020年12月期间所有接受CSVA放置用于血液透析血管通路的患者,共109例(女性55例),平均年龄67.2±13.6岁,均无建立自体动静脉瘘的选项。
主要发现
- 一年原发、原发辅助和继发通畅率分别为37.6%、59.0%和73.3%;两年分别为19.9%、42.5%和54.9%。
- 平均随访26±18个月期间,5例(4.6%)发生通路感染,无相关死亡。
- 随访期间32例(29.4%)死亡,13例(11.9%)接受肾移植,这些患者在移植前均未出现免疫转换。
- 采用Fine-Gray方法计算竞争风险(死亡和肾移植)下的不良事件累积发生率,一年和两年通路丢失率分别为9.2%和18%。
- 57.8%的患者发生狭窄,主要位于流出道(45.9%),49.5%发生血栓形成。
临床怎么用
- 作者认为,对于存在血管通路感染危险因素(如大腿置入、高龄、糖尿病、免疫抑制状态、肥胖或感染人工血管翻修)且静脉资源耗竭的患者,CSVA可作为ePTFE移植物的潜在替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the outcomes of cold stored saphenous vein allografts (CSVAs) for haemodialysis vascular access. METHODS: A retrospective, two centre study was conducted between January 2016 and December 2020 of all patients who had CSVA placement for haemodialysis vascular access. Primary, primary assisted, and secondary patency were analysed, as well as procedural complications and re-interventions. RESULTS: One hundred and nine patients (n = 55 women) with a mean age of 67.2 ± 13.6 years, with no options for creating an autogenous arteriovenous fistula, were included in the study. At one year, primary, primary assisted, and secondary patency were 37.6%, 59.0%, and 73.3%, respectively; and at two years 19.9%, 42.5%, and 54.9%, respectively. During a mean follow up period of 26 ± 18 months, five patients (4.6%) had an access infection, with no related death. During the follow up period, 32 patients (29.4%) died and 13 patients (11.9%) underwent a kidney transplant. None of these patients showed immunoconversion before transplantation. The cumulative incidence of adverse events by the Fine-Gray method was calculated. Considering competing risks (death and renal transplantation), 9.2% of patients lost their vascular access at one year and 18% at two years. Moreover, 57.8% patients had stenosis, mainly on the outflow (45.9%), and 49.5% had thrombosis. CONCLUSION: With a comparable patency rate associated with a low infection rate, CSVA offers a potential alternative to expanded polytetrafluoroethylene grafts. This creates haemodialysis vascular access when the venous capital is exhausted in patients with reported risk factors for vascular access infection, i.e., insertion in the thigh, advanced age, diabetes mellitus, immunocompromised state, obesity, or revision of an infected prosthetic graft.
引用
- Cherkaoui R, Picard E, Branchereau P, et al. Editor's Choice - Outcomes of Cold Stored Saphenous Vein Allografts for Haemodialysis Vascular Access. Eur J Vasc Endovasc Surg. 2024. PMID: 38723741. doi:10.1016/j.ejvs.2024.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。